期刊文献+

磁性聚乳酸-羟基乙酸氧化苦参碱纳米粒的制备及其特性 被引量:4

Preparation and characterization of magnetic poly D,L-lactide-co-glycolide oxymatrine nanoparticles
下载PDF
导出
摘要 目的研究磁性聚乳酸-羟基乙酸氧化苦参碱纳米粒(M-PLGA-OM-NP)的制备工艺,并对纳米粒子进行评价。方法运用复乳法制备M-PLGA-OM-NP,通过透射电子显微镜观察纳米粒形态,并对纳米粒的平均粒径、载药量、包封率、体外释药情况等进行评价。结果纳米粒外观呈规则球形,其平均粒径为146.5 nm,载药量为7.61%,包封率为44.8%。突释后至第72小时,纳米粒维持较稳定的释药速度,累积释放达52.9%。72~240 h,药物释放缓慢,累计释放约为16.6%,体外释放符合Ritger peppas方程lny=1.280 6+lnt。氧化苦参碱药性不受温度影响。结论获得了较满意的M-PLGA-OM-NP制备工艺,其过程简单,粒子性状符合要求。 Objective To study the preparation technique for magnetic poly D,L-lactide-co-glycolide oxymatrine nanoparticles(M-PLGA-OM-NP) and to characterize the resultant product.Methods M-PLGA-OM-NP were prepared by using multiple emulsion process.The morphology of the prepared nanoparticles was observed by transmission electron microscope.The mean diameter,encapsulation ratio,and drug loading rate of the particles were also evaluated.Results The nanoparticles had a regular spherical surface.The mean diameter of the nanoparticles was 146.5 nm.The mean drug loading and entrapment efficiency were 7.61 % and 44.8 % respectively.Among burst release and 72 hours,nanoparticles maintained a stable release rate,cumulative release amount to 52.9 %.It maintained slow drug release at 72-240 hours,cumulative release about 16.6 %.In vitro release conformed to Ritger peppas equation,lny = 1.280 6 + lnt.Conclusion It is demonstrated that M-PLGA-OM-NP with satisfactory quality could be obtained using this method,which can meet the requirement of pharmaceutics.
出处 《生物医学工程与临床》 CAS 2012年第3期213-217,共5页 Biomedical Engineering and Clinical Medicine
基金 2005年上海市卫生局科技发展基金(054123)
关键词 氧化苦参碱 聚乳酸-羟基乙酸 磁性纳米粒 oxymatrine poly D L-lactic-co-glycolic acid magnetic nanoparticles
  • 相关文献

参考文献8

二级参考文献25

共引文献321

同被引文献93

  • 1仵文英,黄洁,刘硕,李兴华,蔡艳.苦参碱隐形脂质体的药代动力学和组织分布研究[J].中国中药杂志,2009,34(6):751-755. 被引量:13
  • 2Chang-QingLi,Yu-TongZhu,Feng-XueZhang,Lin-ChunFu,Xiao-HuiLi,YiCheng,Xiang-YangLi.Anti-HBV effect of liposome-encapsulated matrine in vitro ana in vivo[J].World Journal of Gastroenterology,2005,11(3):426-428. 被引量:12
  • 3董勤,蔡洪培,张忠兵,高申.磁性聚乳酸-羟基乙酸氧化酚砷纳米微粒的制备及其特性[J].第二军医大学学报,2006,27(12):1355-1357. 被引量:2
  • 4Tartaj P, Puerto Morales M, Veintemillas-Verdaguer S, et al. The preparation of magnetic nanoparticles for applications in biomedicine [J]. J. Phys. D: Appl. Phys.2003(36):R182-R197.
  • 5Lu A-H, Salabas E L, and Schfi th F. Magnetic Nanoparticles: Synthesis, Protection, Functionalization and Application [J]. Angew. Chem. Int. Ed.2007(46):1222-1244.
  • 6Kumar C R, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery [J] Adv. Drug Deliver. Rev., 2011 (63) : 789-808.
  • 7Cotter T G,AI-Rubeai M. Cell death (apoptosis) in cell culture systems[J]. Trends Biotechnol.,1995,13 (4) 150-155.
  • 8任杰,王佐,滕新荣,等.-种可生物降解聚合物磁性载药微球的制备方法[P].中国,CNl931129A.2007.03.21.
  • 9G6 mez-Lopera S A, Plaza R C and Delgado A V. Synthesis and Characterization of Spherical Magnetite/Biodegradable Polymer Composite Particles [J]. J. Colloid Interf. Sci.,2001,240:40-47.
  • 10Nkansah M K, Thakral D and Shapiro E M. Magnetic poly(lactide-co-glycolide) (PLGA) and cellulose particles for MRI-based cell tracking[J]. Magn. Reson. Meal.,2011,65(6):1776-1785.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部